Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
07 déc. 2022 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
07 nov. 2022 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
03 oct. 2022 07h30 HE
|
Atsena Therapeutics
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM,...
Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
21 sept. 2022 07h30 HE
|
Atsena Therapeutics
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a...
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
27 juil. 2022 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
02 mai 2022 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
18 oct. 2021 07h15 HE
|
Atsena Therapeutics
Subretinal delivery of RS1 using AAV capsid that spreads laterally beyond the injection site overcomes challenges associated with intravitreal delivery DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE)...
Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
16 août 2021 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
12 juil. 2021 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1
28 juin 2021 07h30 HE
|
Atsena Therapeutics
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...